ArticleExperimental and therapeutic medicine2018
Protective effects of resveratrol improve cardiovascular function in rats with diabetes.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial.Journal of assisted reproduction and genetics · 2019Trial
- The Nutraceutical Promise ofBiology · 2026Review
- The Multidirectional Biological Activity of Resveratrol: Molecular Mechanisms, Systemic Effects and Therapeutic Potential-A Review.Nutrients · 2026Review
- Targeting L-arginine/NO/cGMP/KFrontiers in pharmacology · 2025Review
- Targeting Retinol-Binding Protein 4 (RBP4) in the Management of Cardiometabolic Diseases.Cardiovascular toxicology · 2023Review
- Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice.Frontiers in pharmacology · 2023Review
- Resveratrol as a Promising Polyphenol in Age-Associated Cardiac Alterations.Oxidative medicine and cellular longevity · 2022Article
- Resveratrol ameliorated endothelial injury of thoracic aorta in diabetic mice and Gly-LDL-induced HUVECs through inhibiting TLR4/HIF-1α.Journal of cellular and molecular medicine · 2021Article
- Therapeutic Potential of Polyphenols in the Management of Diabetic Neuropathy.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Food Bioactive Compounds and Emerging Techniques for Their Extraction: Polyphenols as a Case Study.Foods (Basel, Switzerland) · 2020Review
- 3D printed composite scaffolds with dual small molecule delivery for mandibular bone regeneration.Biofabrication · 2020Article
- Resveratrol and Diabetic Cardiomyopathy: Focusing on the Protective Signaling Mechanisms.Oxidative medicine and cellular longevity · 2020Review
- Quercetin, Epigallocatechin Gallate, Curcumin, and Resveratrol: From Dietary Sources to Human MicroRNA Modulation.Molecules (Basel, Switzerland) · 2019Review
- Evolvement of nutraceutical onion plants engineered for resveratrol biosynthetic pathway.Plant cell reports · 2019Article
- A comparison of resveratrol and other polyphenolic compounds on Notch activation and endothelial cell activity.PloS one · 2019Article
- A Novel Resveratrol-Arsenic Trioxide Combination Treatment Synergistically Induces Apoptosis of Adriamycin-Selected Drug-Resistant Leukemia K562 Cells.Journal of Cancer · 2019Article
- Resveratrol: A Double-Edged Sword in Health Benefits.Biomedicines · 2018Review
- Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resveratrol is a flavonoid with a stilbene structure that is able to suppress acute pulmonary thromboembolism-induced pulmonary artery hypertension. Furthermore, it possesses anti-cancer and antioxidant properties, is able to regulate blood lipids and increase life expectancy. In the present study, it was evaluated whether the protective effect of resveratrol was able to improve cardiovascular function in rats with diabetes. The effects of resveratrol on blood glucose, body weight, heart/body weight ratio, plasma triglyceride levels, heart rate, aspartate transaminase (AST)/alanine transaminase (ALT) ratio and total plasma insulin were evaluated. Levels of inflammation and oxidative stress were also evaluated using ELISA kits, and the expressions of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and phosphorylated (p)-p38 protein were evaluated via western blot analysis. The results demonstrated that administration of resveratrol in rats with diabetes-related myocardial infarction (DRMI) significantly reduced blood glucose, body weight, plasma triglyceride levels, heart rate and AST/ALT ratio (all P<0.01) and significantly increased total plasma insulin (P<0.01). Furthermore, resveratrol significantly reduced levels of inflammation factors (P<0.01) and malondialdehyde, a marker for oxidative stress, in rats with DRMI (P<0.01). Resveratrol significantly increased the expression of eNOS (P<0.01) and suppressed the expression of VEGF and p-p38 (both P<0.01) in rats with DRMI. These results suggest that treatment with resveratrol is able to improve cardiovascular function via inhibition of eNOS and VEGF, and suppression of p38 phosphorylation in rats with DRMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.